News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PCI Biotech Reports Successful Completion of the Third Dose Group in the Phase I/II Amphinex(R) Trial


3/16/2010 9:52:58 AM

OSLO--(BUSINESS WIRE)--PCI Biotech reported today that it has completed the treatment of the third dose group in the phase I/II study of its proprietary photosensitiser Amphinex® used in combination with the cytotoxic agent bleomycin in cancer patients. Complete clinical regression of all evaluable treated tumours is observed within a few weeks of treatment also on patients at the third dose level, although one patient died of the underlying disease before complete clinical regression could be achieved. No drug-related serious adverse events have been reported.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES